[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR085443A1 - AEROSOL MEDICINAL FORMULATIONS THAT DO NOT DAMAGE THE OZONE LAYER AND WITH LOW GREENHOUSE EFFECT - Google Patents

AEROSOL MEDICINAL FORMULATIONS THAT DO NOT DAMAGE THE OZONE LAYER AND WITH LOW GREENHOUSE EFFECT

Info

Publication number
AR085443A1
AR085443A1 ARP120100894A AR085443A1 AR 085443 A1 AR085443 A1 AR 085443A1 AR P120100894 A ARP120100894 A AR P120100894A AR 085443 A1 AR085443 A1 AR 085443A1
Authority
AR
Argentina
Prior art keywords
metered dose
ozone layer
greenhouse effect
bromide
damage
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Julio Cesar Vega
Fernando Toneguzzo
Original Assignee
Pablo Cassara S R L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/052,054 external-priority patent/US20120207685A1/en
Application filed by Pablo Cassara S R L Lab filed Critical Pablo Cassara S R L Lab
Publication of AR085443A1 publication Critical patent/AR085443A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhaladores farmacéuticos presurizados de dosis medida (IDM) que contienen una composición libre de CFC (clorofluorocarburos) y total o parcialmente libre de hidrofluoroalcanos (HFA), que permite la fabricación de aerosoles para uso medicinal sin dañar la capa de ozono de la atmósfera y con bajo o insignificante efecto invernadero.Reivindicación 1: Un inhalador farmacéutico presurizado de dosis medida, caracterizado porque comprende: al menos un ingrediente farmacéutico activo; al menos un propulsor de hidrocarburo; al menos un alcohol alifático entre 0,1 y 30% p/p; al menos un surfactante entre 0,001 y 5% p/p; un medio de administración que comprende, además, un bidón provisto de una válvula dosificadora que libera entre 20 y 200 mL de formulación por descarga. Reivindicación 10: El inhalador farmacéutico presurizado de dosis medida de la reivindicación 1, caracterizado porque dicho ingrediente activo está seleccionado de un grupo de drogas administradas por inhalación que comprende salbutamol, sulfato de salbutamol, dipropionato de beclometasona, budesonida, fumarato de formoterol, propionato de fluticasona, fumarato de fluticasona, furoato de mometasona, xinafoato de salmeterol, ciclesonida, bromuro de ipratropio, bromuro de oxitropio y bromuro de tiotropio.Pressurized pharmaceutical metered dose inhalers (MDI) containing a composition free of CFC (chlorofluorocarbons) and totally or partially free of hydrofluoroalkanes (HFA), which allows the manufacture of aerosols for medicinal use without damaging the atmosphere's ozone layer and with low or insignificant greenhouse effect. Claim 1: A pressurized pharmaceutical metered dose inhaler, characterized in that it comprises: at least one active pharmaceutical ingredient; at least one hydrocarbon propellant; at least one aliphatic alcohol between 0.1 and 30% w / w; at least one surfactant between 0.001 and 5% w / w; an administration means comprising, in addition, a drum provided with a metering valve that releases between 20 and 200 mL of discharge formulation. Claim 10: The pressurized pharmaceutical metered dose inhaler of claim 1, characterized in that said active ingredient is selected from a group of drugs administered by inhalation comprising salbutamol, salbutamol sulfate, beclomethasone dipropionate, budesonide, formoterol fumarate, propionate fluticasone, fluticasone fumarate, mometasone furoate, salmeterol xinafoate, ciclesonide, ipratropium bromide, oxitropium bromide and tiotropium bromide.

ARP120100894 2011-03-19 2012-03-19 AEROSOL MEDICINAL FORMULATIONS THAT DO NOT DAMAGE THE OZONE LAYER AND WITH LOW GREENHOUSE EFFECT AR085443A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/052,054 US20120207685A1 (en) 2011-02-10 2011-03-19 Non-ozone depleting medicinal formulations with low greenhouse effect

Publications (1)

Publication Number Publication Date
AR085443A1 true AR085443A1 (en) 2013-10-02

Family

ID=49552950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100894 AR085443A1 (en) 2011-03-19 2012-03-19 AEROSOL MEDICINAL FORMULATIONS THAT DO NOT DAMAGE THE OZONE LAYER AND WITH LOW GREENHOUSE EFFECT

Country Status (2)

Country Link
AR (1) AR085443A1 (en)
BR (1) BR102012008322B8 (en)

Also Published As

Publication number Publication date
BR102012008322A2 (en) 2015-08-04
BR102012008322B1 (en) 2019-01-15
BR102012008322B8 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
DK2926855T3 (en) NOSE SPRAY DEVICE
PE20160853A1 (en) COMBINED THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
HRP20180944T1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
PE20011323A1 (en) PHARMACEUTICAL FORMULATIONS IN STABLE SOLUTION FOR PRESSURIZED INHALERS WITH DOSE MEASUREMENT
AR081540A1 (en) PROCESS TO PROVIDE PARTICLES WITH REDUCED ELECTRO-STATIC CHARGES
AR098982A1 (en) COMBINED COMPOSITION OF GLICOPIRRONIUM AND FORMOTEROL BROMIDE IN STABLE PRESSURIZED SOLUTION FOR AEROSOL
JP5800829B2 (en) Aerosol formulation for COPD
AR038641A1 (en) FORMOTEROL SUPERFINE FORMULATION
AR101593A2 (en) FORMOTEROL SUPERFINE FORMULATION
RS52940B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
PE20160155A1 (en) COMPOSITIONS, METHODS AND SYSTEMS FOR THE RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
NZ599900A (en) Pharmaceutical suspension aerosol formulations for use in metered dose inhalers
HRP20231729T1 (en) Combination therapy for copd
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
AR123674A2 (en) PHARMACEUTICAL COMPOSITION IN AEROSOL OF FORMOTEROL AND BECLOMETHASONE DIPROPIONATE
CL2023000998A1 (en) Pharmaceutical formulation for pressurized metered dose inhaler
US10960154B2 (en) Aerosol device
PE20011271A1 (en) FORMULATIONS CONTAINING A GLUCOCORTICOID DRUG FOR THE TREATMENT OF BRONCOPULMONARY DISEASES
US20130104881A1 (en) Stabilized Metered Dose Inhaler
JP2004529108A5 (en)
CO6270213A2 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MONTELUKAST ACID AND A DEPDE-4 UNHIBITOR OR AN INHALED CORTICOESTEROID FOR INHALATION ADMINISTRATION
WO2011061498A3 (en) Inhalation solutions
ES2259915B1 (en) NEW STABLE FORMULATION OF AEROSOLS IN SUSPENSION AND PROCEDURE OF OBTAINING.
JP2014527056A5 (en)
AR085443A1 (en) AEROSOL MEDICINAL FORMULATIONS THAT DO NOT DAMAGE THE OZONE LAYER AND WITH LOW GREENHOUSE EFFECT

Legal Events

Date Code Title Description
FC Refusal